Peptides in Breast Cancer: From Tumor-Targeting to Drug Delivery and Immunotherapy
Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates, antimicrobial peptides, and emerging peptide-based drug delivery systems.
Quick Facts
What This Study Found
Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates, antimicrobial peptides, and emerging peptide-based drug delivery systems.
Key Numbers
Review article covering multiple peptide applications — specific data from individual studies referenced within.
How They Did This
Clinical or preclinical study with methodology detailed in the full publication.
Why This Research Matters
This finding has implications for the millions of patients using or considering peptide-based therapies.
The Bigger Picture
This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.
What This Study Doesn't Tell Us
Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.
Questions This Raises
- ?What are the long-term implications of these findings?
- ?How do these results compare to other studies in this area?
- ?What further research is needed to confirm and extend these findings?
Trust & Context
- Key Stat:
- Key finding Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates
- Evidence Grade:
- Evidence grade assessment based on study design and methodology detailed in the full publication.
- Study Age:
- Published in 2025. Reflects current state of peptide therapeutic research.
- Original Title:
- Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies.
- Published In:
- Pathology, research and practice, 269, 155946 (2025)
- Authors:
- Alaei, Elmira, Hashemi, Farid, Farahani, Najma, Tahmasebi, Safa, Nabavi, Noushin, Daneshi, Salman, Mahmoodieh, Behnaz, Rahimzadeh, Payman, Taheriazam, Afshin, Hashemi, Mehrdad
- Database ID:
- RPEP-09834
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this study mean for patients?
Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates, antimicrobial peptides, and emerging peptide-based drug delivery systems.
How reliable are these findings?
The evidence level depends on study design. Clinical trials provide stronger evidence than case reports. Consult the full publication and discuss with your healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09834APA
Alaei, Elmira; Hashemi, Farid; Farahani, Najma; Tahmasebi, Safa; Nabavi, Noushin; Daneshi, Salman; Mahmoodieh, Behnaz; Rahimzadeh, Payman; Taheriazam, Afshin; Hashemi, Mehrdad. (2025). Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies.. Pathology, research and practice, 269, 155946. https://doi.org/10.1016/j.prp.2025.155946
MLA
Alaei, Elmira, et al. "Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies.." Pathology, 2025. https://doi.org/10.1016/j.prp.2025.155946
RethinkPeptides
RethinkPeptides Research Database. "Peptides in breast cancer therapy: From mechanisms to emergi..." RPEP-09834. Retrieved from https://rethinkpeptides.com/research/alaei-2025-peptides-in-breast-cancer
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.